DKK1,251.50
2.61% yesterday
Copenhagen, Apr 04, 05:00 pm CET
ISIN
DK0010272202
Symbol
GMAB
Sector

Genmab A/S Target price 2025 - Analyst rating & recommendation

Genmab A/S Classifications & Recommendation:

Buy
65%
Hold
31%
Sell
4%

Genmab A/S Price Target

Target Price DKK2,181.26
Price DKK1,251.50
Potential
Number of Estimates 19
19 Analysts have issued a price target Genmab A/S 2026 . The average Genmab A/S target price is DKK2,181.26. This is higher than the current stock price. The highest price target is
DKK3,580.00 186.06%
register free of charge
, the lowest is
DKK1,000.00 20.10%
register free of charge
.
A rating was issued by 26 analysts: 17 Analysts recommend Genmab A/S to buy, 8 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Genmab A/S stock has an average upside potential 2026 of . Most analysts recommend the Genmab A/S stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion DKK 21.53 25.12
30.67% 16.68%
EBITDA Margin 34.45% 34.71%
0.49% 0.75%
Net Margin 36.07% 26.44%
40.35% 26.71%

23 Analysts have issued a sales forecast Genmab A/S 2025 . The average Genmab A/S sales estimate is

DKK25.1b
Unlock
. This is
16.68% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
DKK28.4b 31.88%
Unlock
, the lowest is
DKK22.4b 4.06%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 DKK21.5b 30.67%
2025
DKK25.1b 16.68%
Unlock
2026
DKK28.8b 14.77%
Unlock
2027
DKK32.9b 14.03%
Unlock
2028
DKK37.4b 13.86%
Unlock
2029
DKK39.2b 4.64%
Unlock

22 Genmab A/S Analysts have issued a net profit forecast 2025. The average Genmab A/S net profit estimate is

DKK6.6b
Unlock
. This is
14.76% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
DKK8.4b 8.30%
Unlock
, the lowest is
DKK5.2b 33.79%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 DKK7.8b 83.39%
2025
DKK6.6b 14.49%
Unlock
2026
DKK7.9b 19.43%
Unlock
2027
DKK9.6b 21.09%
Unlock
2028
DKK12.7b 32.11%
Unlock
2029
DKK13.7b 8.05%
Unlock

Net Margin

2024 36.07% 40.35%
2025
26.44% 26.71%
Unlock
2026
27.51% 4.05%
Unlock
2027
29.21% 6.18%
Unlock
2028
33.90% 16.06%
Unlock
2029
35.00% 3.24%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share DKK 122.21 104.50
83.39% 14.49%
P/E 11.98
EV/Sales 2.37

22 Analysts have issued a Genmab A/S forecast for earnings per share. The average Genmab A/S EPS is

DKK104.50
Unlock
. This is
14.76% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
DKK132.76 8.30%
Unlock
, the lowest is
DKK81.17 33.79%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 DKK122.21 83.39%
2025
DKK104.50 14.49%
Unlock
2026
DKK124.81 19.44%
Unlock
2027
DKK151.13 21.09%
Unlock
2028
DKK199.65 32.10%
Unlock
2029
DKK215.73 8.05%
Unlock

P/E ratio

Current 10.21 67.34%
2025
11.98 17.34%
Unlock
2026
10.03 16.28%
Unlock
2027
8.28 17.45%
Unlock
2028
6.27 24.28%
Unlock
2029
5.80 7.50%
Unlock

Based on analysts' sales estimates for 2025, the Genmab A/S stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.76 58.25%
2025
2.37 14.23%
Unlock
2026
2.06 12.86%
Unlock
2027
1.81 12.30%
Unlock
2028
1.59 12.17%
Unlock
2029
1.52 4.43%
Unlock

P/S ratio

Current 3.69 55.33%
2025
3.17 14.30%
Unlock
2026
2.76 12.87%
Unlock
2027
2.42 12.30%
Unlock
2028
2.13 12.17%
Unlock
2029
2.03 4.44%
Unlock

Current Genmab A/S Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
REDBURN ATLANTIC
Locked
Locked
Locked Jan 02 2025
TD COWEN
Locked
Locked
Locked Dec 16 2024
DNB MARKETS
Locked
Locked
Locked Dec 11 2024
GUGGENHEIM SECURITIES LLC
Locked
Locked
Locked Dec 10 2024
HSBC
Locked
Locked
Locked Nov 24 2024
TRUIST SECURITIES
Locked
Locked
Locked Nov 14 2024
H.C. WAINWRIGHT & CO., LLC
Locked
Locked
Locked Oct 15 2024
Analyst Rating Date
Locked
REDBURN ATLANTIC:
Locked
Locked
Jan 02 2025
Locked
TD COWEN:
Locked
Locked
Dec 16 2024
Locked
DNB MARKETS:
Locked
Locked
Dec 11 2024
Locked
GUGGENHEIM SECURITIES LLC:
Locked
Locked
Dec 10 2024
Locked
HSBC:
Locked
Locked
Nov 24 2024
Locked
TRUIST SECURITIES:
Locked
Locked
Nov 14 2024
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
Locked
Oct 15 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today